AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1728908 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol with weight loss (≥4.5 kg)
Number of subjects: 787
Study 1728908 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone with weight loss (≥2.25 kg)
Number of subjects: 787
Study 6142878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (alpha 1‐adrenoceptor blockade)
Number of subjects: 0
Study 6142878 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta 1‐adrenoceptor blockade)
Number of subjects: 0
Study 6142878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (nonselective beta‐adrenoceptor blockade)
Number of subjects: 0
Study 6142878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31660991 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg (CAFF300)
Number of subjects: 12
Study 31660991 — intervention group
Group type: EXPERIMENTAL
Intervention: TeaCrine® 300 mg (TEA300)
Number of subjects: 12
Study 31660991 — intervention group
Group type: EXPERIMENTAL
Intervention: TeaCrine® + Caffeine (COMBO; 150 mg/150 mg)
Number of subjects: 12
Study 31660991 — intervention group
Group type: COMPARATOR
Intervention: Placebo 300 mg (PLA)
Number of subjects: 12
Study 28976114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based complementary feeding
Number of subjects: 0
Study 28976114 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme food insecurity
Number of subjects: 0
Study 28976114 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic constraints
Number of subjects: 0
Study 27556294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsing magnetic field (4mT intensity, 15-Hz frequency, 20min per session, 2 times per week for 2 months, 16 sessions)
Number of subjects: 63
Study 27556294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (magnetically inactive field, 20min per session, 2 times per week for 2 months, 16 sessions)
Number of subjects: 63
Study 24760791 — intervention group
Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 147
Study 24760791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 23031354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glucose (LG; 2.5 mg/kg per minute)
Number of subjects: 11
Study 20682017 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth tooth extraction
Number of subjects: 50
Study 20682017 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study 16978741 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 80
Study 16978741 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 80
Study 15846265 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhospital cardiac catheterization
Number of subjects: 8286
Study 11981396 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg oral tablet taken three times per day)
Number of subjects: 221
Study 11981396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (150 mg oral capsule taken once daily with dinner)
Number of subjects: 221
Study 9462525 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC
Number of subjects: 90
Study 9462525 — intervention group
Group type: EXPERIMENTAL
Intervention: OMC
Number of subjects: 90
Study 9462525 — intervention group
Group type: COMPARATOR
Intervention: CMC
Number of subjects: 90
Study 7781863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 7781863 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm (HRT)
Number of subjects: 0
Study 7781863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prempak‐C (HRT)
Number of subjects: 0
Study 7781863 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (general)
Number of subjects: 0
Study 1922180 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable frequency, short‐duration trains (VFTs) of electrical pulses
Number of subjects: 12
Study 1922180 — intervention group
Group type: COMPARATOR
Intervention: Constant frequency, short‐duration trains (CFTs) of 80, 40 or 20 pps
Number of subjects: 12
Study 7255508 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 12
Study 7255508 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (1 mg/kg)
Number of subjects: 12
Study 31845894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy (23-month duration after one month of DAPT)
Number of subjects: 2565
Study 31845894 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment (12-month DAPT followed by 12 months of aspirin)
Number of subjects: 2565
Study 31845894 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 2565
Study 31845894 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment
Number of subjects: 2565
Study 31150789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame Oral Immunotherapy (OIT)
Number of subjects: 60
Study 31150789 — intervention group
Group type: COMPARATOR
Intervention: Control (observational)
Number of subjects: 60
Study 28351405 — intervention group
Group type: EXPERIMENTAL
Intervention: Project HEAL intervention (three-workshop cancer educational series)
Number of subjects: 375
Study 25736340 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored interactive health communication application (IHCA)
Number of subjects: 561
Study 25736340 — intervention group
Group type: COMPARATOR
Intervention: Control website (non-tailored)
Number of subjects: 561
Study 23962572 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during hysteroscopy
Number of subjects: 356
Study 23962572 — intervention group
Group type: COMPARATOR
Intervention: No music during hysteroscopy
Number of subjects: 356
Study 22848592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Monitor based on skin conductance (NFSC)
Number of subjects: 44
Study 22848592 — intervention group
Group type: COMPARATOR
Intervention: Standard pain therapy procedures
Number of subjects: 44
Study 20354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense administration of paclitaxel
Number of subjects: 0
Study 20354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of platinum and paclitaxel
Number of subjects: 0
Study 20354543 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of pegylated liposomal doxorubicin combined with carboplatin
Number of subjects: 0
Study 20354543 — intervention group
Group type: COMPARATOR
Intervention: Standard paclitaxel and carboplatin
Number of subjects: 0
Study 17523994 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute body scan (experimental group n = 15)
Number of subjects: 30
Study 17523994 — intervention group
Group type: COMPARATOR
Intervention: Natural history passage (control group n = 15)
Number of subjects: 30
Study 16169422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg/day
Number of subjects: 0
Study 16169422 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 80 mg/day
Number of subjects: 0
Study 12471862 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis treatment
Number of subjects: 593
Study 12471862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes treatment
Number of subjects: 593
Study 12471862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment
Number of subjects: 593
Study 12471862 — intervention group
Group type: COMPARATOR
Intervention: Arthritis control
Number of subjects: 593
Study 12471862 — intervention group
Group type: COMPARATOR
Intervention: Diabetes control
Number of subjects: 593
Study 12471862 — intervention group
Group type: COMPARATOR
Intervention: Hypertension control
Number of subjects: 593
Study 9472846 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (5-10 mg/day)
Number of subjects: 40
Study 9472846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7611312 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty first
Number of subjects: 271
Study 7611312 — intervention group
Group type: COMPARATOR
Intervention: Topical medication first
Number of subjects: 271
Study 7611312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 271
Study 2203250 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat evening meal (41 g fat)
Number of subjects: 8
Study 2203250 — intervention group
Group type: COMPARATOR
Intervention: Standard evening meal (unsupplemented)
Number of subjects: 8
Study 615785 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional barium meal
Number of subjects: 101
Study 615785 — intervention group
Group type: EXPERIMENTAL
Intervention: Double contrast examination
Number of subjects: 101
Study 615785 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy of the stomach and duodenum
Number of subjects: 101
Study 615785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary X-ray examination
Number of subjects: 101
Study 615785 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary gastroscopy
Number of subjects: 101
Study 31051508 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing saturated fatty acids (SFAs) with polyunsaturated fatty acids (PUFAs)
Number of subjects: 99
Study 26068327 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h/week of specialist‐taught physical education (PE) from grades 1 to 6
Number of subjects: 86
Study 26068327 — intervention group
Group type: COMPARATOR
Intervention: 40 min/week of home‐room teacher‐taught physical education (PE) from grades 1 to 6
Number of subjects: 86
Study 23075919 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) counseling up to 6 months
Number of subjects: 1028
Study 23075919 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation and continuation
Number of subjects: 1028
Study 23075919 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) by 3 months
Number of subjects: 1028
Study 23084167 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence (EI) educational program
Number of subjects: 479
Study 23084167 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 479
Study 19067285 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 5 to 10 ppm
Number of subjects: 12
Study 19067285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oxygen)
Number of subjects: 12
Study 19067285 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12
Study 17688822 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand video‐assisted thoracoscopic surgery (HVATS)
Number of subjects: 39
Study 17688822 — intervention group
Group type: COMPARATOR
Intervention: Ivor‐Lewis surgery
Number of subjects: 39
Study 17688822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HVATS and Ivor‐Lewis)
Number of subjects: 39
Study 15139874 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling Related Cognition Scale (GRCS)
Number of subjects: 968
Study 15139874 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis
Number of subjects: 968
Study 15139874 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA)
Number of subjects: 968
Study 15139874 — intervention group
Group type: COMPARATOR
Intervention: South Oaks Gambling Screen (SOGS)
Number of subjects: 968
Study 15139874 — intervention group
Group type: COMPARATOR
Intervention: Motivation Towards Gambling Scale (MTGS)
Number of subjects: 968
Study 15139874 — intervention group
Group type: COMPARATOR
Intervention: Depression Anxiety Stress Scale (DASS-21)
Number of subjects: 968
Study 11560385 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding (n = 29)
Number of subjects: 59
Study 11560385 — intervention group
Group type: COMPARATOR
Intervention: Vertical banded gastroplasty (n = 30)
Number of subjects: 59
Study 9476183 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/lansoprazole 15 mg
Number of subjects: 132
Study 9476183 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/placebo
Number of subjects: 132
Study 9476183 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg/ranitidine 150 mg
Number of subjects: 132
Study 9476183 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg/placebo
Number of subjects: 132
Study 9476183 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole (half dose formulation)
Number of subjects: 132
Study 7964842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) therapy
Number of subjects: 76
Study 7964842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 3680603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 1 mg alprazolam
Number of subjects: 13
Study 3680603 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of 1 mg alprazolam
Number of subjects: 13
Study 29950827 — intervention group
Group type: EXPERIMENTAL
Intervention: LLN+/FR+
Number of subjects: 2607
Study 29950827 — intervention group
Group type: EXPERIMENTAL
Intervention: LLN-/FR+
Number of subjects: 2607
Study 29950827 — intervention group
Group type: EXPERIMENTAL
Intervention: LLN-/FR-
Number of subjects: 2607
Study 29950827 — intervention group
Group type: COMPARATOR
Intervention: LLN+/FR+ vs LLN-/FR-
Number of subjects: 2607
Study 29950827 — intervention group
Group type: COMPARATOR
Intervention: LLN-/FR+ vs LLN+/FR+
Number of subjects: 2607
Study 26771737 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (30 mg/day, titrated over 3 weeks)
Number of subjects: 186
Study 26771737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 24410954 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA supplement (2.3 g daily for 6 months)
Number of subjects: 204
Study 24410954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 22818964 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitroflow valve
Number of subjects: 276
Study 20350147 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily
Number of subjects: 596
Study 20350147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 18595291 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of tasks from a list
Number of subjects: 3
Study 18595291 — intervention group
Group type: COMPARATOR
Intervention: Yoked-control condition (tasks assigned by a trainer)
Number of subjects: 3
Study 16086704 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Number of subjects: 458
Study 16086704 — intervention group
Group type: COMPARATOR
Intervention: 10-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Number of subjects: 458
Study 16086704 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day rabeprazole-based triple therapy
Number of subjects: 458
Study 16086704 — intervention group
Group type: COMPARATOR
Intervention: 10-day rabeprazole-based triple therapy
Number of subjects: 458
Study 11744802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic intake of vegetable protein added to animal protein diet
Number of subjects: 14
Study 11744802 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting vegetable protein for some of the animal protein in the diet
Number of subjects: 14
Study 11744802 — intervention group
Group type: COMPARATOR
Intervention: Control dietary program (not specified in detail)
Number of subjects: 14
Study 10075960 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Digestive Disorders Quality of Life Questionnaire (FDDQL)
Number of subjects: 401
Study 8834642 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive patients with glomerulonephritis
Number of subjects: 0
Study 8834642 — intervention group
Group type: COMPARATOR
Intervention: Normotensive patients with glomerulonephritis
Number of subjects: 0
Study 2184180 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Q wave infarction
Number of subjects: 777
Study 2184180 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferoposterior Q wave infarction
Number of subjects: 777
Study 2184180 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q wave infarction
Number of subjects: 777
Study 6116728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + cimetidine (300 mg q.i.d.)
Number of subjects: 19
Study 6116728 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + placebo
Number of subjects: 19
Study 6116728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + terbutaline (2.5 mg q.i.d.)
Number of subjects: 19
Study 6116728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + cyproheptadine (4 mg q.i.d.)
Number of subjects: 19
Study 6116728 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine pamoate (25 mg q.i.d.) + chlorpheniramine (4 mg q.i.d.)
Number of subjects: 19
Study 30280927 — intervention group
Group type: COMPARATOR
Intervention: Maternal prepregnancy overweight/obesity (BMI ≥ 25 kg/m2)
Number of subjects: 194
Study 30280927 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight women
Number of subjects: 194
Study 28130627 — intervention group
Group type: COMPARATOR
Intervention: Traditional Resistance Training (TRAD)
Number of subjects: 32
Study 28130627 — intervention group
Group type: EXPERIMENTAL
Intervention: Crescent Pyramid (CP)
Number of subjects: 32
Study 28130627 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-Set (DS)
Number of subjects: 32
Study 24941138 — intervention group
Group type: EXPERIMENTAL
Intervention: Black cohosh extract 40 mg/day
Number of subjects: 54
Study 24941138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 23328330 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 to 50 mg/d)
Number of subjects: 448
Study 23328330 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproate (500 to 750 mg/d)
Number of subjects: 448
Study 23328330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 448
Study 21461792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg·kg(‐1) and 4 μg·kg(‐1) combined)
Number of subjects: 101
Study 21461792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 μg·kg(‐1))
Number of subjects: 101
Study 21461792 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 μg·kg(‐1))
Number of subjects: 101
Study 21461792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 101
Study 19125241 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg idebenone
Number of subjects: 25
Study 19125241 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg idebenone
Number of subjects: 25
Study 19125241 — intervention group
Group type: EXPERIMENTAL
Intervention: idebenone (up to 2,250 mg/day)
Number of subjects: 25
Study 19125241 — intervention group
Group type: EXPERIMENTAL
Intervention: idebenone
Number of subjects: 25
Study 17910227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin adhesives and a dentin desensitizer
Number of subjects: 55
Study 17910227 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study 14752632 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted technique for primary placement of the peritoneal portion of shunt catheter (n=11)
Number of subjects: 17
Study 14752632 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted technique for evaluation of shunt patency and repositioning (n=6)
Number of subjects: 17
Study 11707794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 microg
Number of subjects: 30
Study 11707794 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine 0.25%, 12 mL
Number of subjects: 30
Study 9489599 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg hydroxocobalamin
Number of subjects: 10
Study 9489599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 microg hydroxocobalamin
Number of subjects: 10
Study 9489599 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg to 1500 microg hydroxocobalamin
Number of subjects: 10
Study 7811785 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowed respiration rate (RR) training
Number of subjects: 0
Study 7811785 — intervention group
Group type: COMPARATOR
Intervention: Traditional frontal electromyographic (EMG) biofeedback
Number of subjects: 0
Study 7811785 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no feedback)
Number of subjects: 0
Study 3197368 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 120
Study 3197368 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 120
Study 3197368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31329360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (continuation from INPULSIS®)
Number of subjects: 215
Study 31329360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (initiation in INPULSIS®‐ON after placebo)
Number of subjects: 215
Study 31329360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (continuation in INPULSIS®‐ON)
Number of subjects: 215
Study 31329360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in INPULSIS®)
Number of subjects: 215
Study 30544518 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (0 to 7 mg/kg/day for six months)
Number of subjects: 109
Study 30544518 — intervention group
Group type: COMPARATOR
Intervention: Control (no DHA supplementation)
Number of subjects: 109
Study 26746147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 100
Study 26746147 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 100
Study 24238592 — intervention group
Group type: EXPERIMENTAL
Intervention: Push as hard as you can
Number of subjects: 13
Study 24238592 — intervention group
Group type: COMPARATOR
Intervention: Push down firmly 5 cm
Number of subjects: 13
Study 24397061 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid injection (triamcinolone 20 mg mixed with lignocaine 2% 1 cc) and topical NSAID cream (diclofenac diethylammonium) twice a day, tab. diclofenac sodium 50 mg twice a day for 3 weeks
Number of subjects: 60